New research in The BMJ and JAMA Neurology links long-term Depo-Provera use to a small increase in meningioma risk. This article explains the findings, puts the risk in context, and explores what it means for those using Depo-Provera for contraception or endometriosis management.
One of the most significant yet often unspoken issues I encounter is period poverty. In Aotearoa, a lack of access to affordable period products is not just a financial issue; it’s a public health crisis that affects education, dignity, and well-being.
For the first time in nine years, there’s a new medical treatment available in New Zealand. Ryeqo (relugolix, estradiol, norethisterone acetate) is now registered for adults of reproductive age who have tried other medical or surgical treatments for their endometriosis.